Table 5 |
||||||||||
|
Genotype frequencies of IL-4/IL-13 variants and production of autoantibodies |
||||||||||
|
Gene |
SNP |
Genotypes |
Anti-CCP statusa |
RF statusa |
||||||
|
|
||||||||||
|
Positive (n) |
Negative (n) |
OR (95% CI) |
P |
Positive (n) |
Negative (n) |
OR (95% CI) |
P |
|||
|
|
||||||||||
|
IL-13 |
rs1800925 |
TT |
17 |
8 |
0.6 (0.3–1.8) |
0.3b |
16 |
7 |
1.0 (0.4–3.0) |
1.0b |
|
CT |
207 |
59 |
1.1 (0.7–1.5) |
0.8 |
170 |
82 |
0.9 (0.7–1.3) |
0.6 |
||
|
CC |
458 |
138 |
1.0 |
387 |
171 |
1.0 |
||||
|
rs1295686 |
TT |
20 |
6 |
1.0 (0.4–3.0) |
1.0b |
16 |
10 |
0.7 (0.3–1.8) |
0.5b |
|
|
CT |
192 |
54 |
1.0 (0.7–1.5) |
0.8 |
161 |
72 |
1.0 (0.7–1.4) |
1.0 |
||
|
CC |
439 |
128 |
1.0 |
367 |
165 |
1.0 |
||||
|
IL-4 |
rs2227284 |
AA |
42 |
14 |
0.8 (0.4–1.7) |
0.5 |
33 |
21 |
0.7 (0.4–14) |
0.3 |
|
AC |
232 |
74 |
0.8 (0.6–1.2) |
0.3 |
202 |
89 |
1.0 (0.8–1.5) |
0.8 |
||
|
CC |
419 |
113 |
1.0 |
338 |
156 |
1.0 |
||||
|
rs2243263 |
CC |
5 |
3 |
0.5 (0.09–3.1) |
0.4b |
5 |
3 |
0.8 (0.1–5.0) |
0.7b |
|
|
AC |
102 |
38 |
0.8 (0.5–1.2) |
0.2 |
89 |
44 |
0.9 (0.6–1.4) |
0.2 |
||
|
AA |
568 |
160 |
1.0 |
465 |
213 |
1.0 |
||||
|
rs2243267 |
CC |
17 |
1 |
5.2 (0.8–218.9) |
0.09b |
13 |
4 |
1.5 (0.4–6.2) |
0.6b |
|
|
CG |
167 |
48 |
1.1 (0.7–1.6) |
0.9 |
142 |
64 |
1.0 (0.7–1.4) |
1.0 |
||
|
GG |
503 |
154 |
1.0 |
422 |
190 |
1.0 |
||||
|
IL-4R |
rs1805010 |
GG |
150 |
43 |
0.8 (0.5–1.4) |
0.4 |
122 |
59 |
0.8 (0.5–1.3) |
0.3 |
|
AG |
341 |
109 |
0.8 (0.5–1.2) |
0.2 |
288 |
136 |
0.8 (0.6–1.2) |
0.3 |
||
|
AA |
196 |
50 |
1.0 |
165 |
64 |
1.0 |
||||
|
rs1801275 |
AA |
31 |
5 |
2.0 (0.7–6.6) |
0.2 |
26 |
9 |
1.4 (0.6–3.4) |
0.6 |
|
|
AG |
241 |
71 |
1.1 (0.8–1.5) |
0.7 |
197 |
92 |
1.0 (0.7–1.4) |
1.0 |
||
|
GG |
416 |
131 |
1.0 |
351 |
165 |
1.0 |
||||
|
|
||||||||||
|
aThe presence of anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) was compared for each single nucleotide polymorphism (SNP) with reference to the commonest genotype. bBy Fisher's exact test for association. CI, confidence interval; OR, odds ratio. |
||||||||||
|
Marinou et al. Arthritis Research & Therapy 2008 10:R80 doi:10.1186/ar2454 |
||||||||||